Publications

Endocrine-related cancer

Androgen receptor moonlighting in the prostate cancer microenvironment.

01-06-2018

Oncogene

Endogenous androgen receptor proteomic profiling reveals genomic subcomplex involved in prostate tumorigenesis.

18-01-2018

Oncotarget

Prognostic factors in men with metastatic castration-resistant prostate cancer treated with cabazitaxel.

05-12-2017

Oncotarget

The adaptive immune system promotes initiation of prostate carcinogenesis in a human c-Myc transgenic mouse model.

07-11-2017

Clinical genitourinary cancer

The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer.

06-09-2017

The Lancet. Oncology

Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial.

01-04-2017

Clinical cancer research : an official journal of the American Association for Cancer Research

Effects of Budesonide on Cabazitaxel Pharmacokinetics and Cabazitaxel-Induced Diarrhea: A Randomized, Open-Label Multicenter Phase II Study.

01-04-2017

Neoplasia (New York, N.Y.)

Randomized Phase III Study to Assess Efficacy and Safety of Adjuvant CAPOX with or without Bevacizumab in Patients after Resection of Colorectal Liver Metastases: HEPATICA study.

01-02-2017

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.

01-09-2016

Oncology

Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer.

22-08-2016

Urology case reports

The Effects of Enzalutamide Monotherapy on Multiparametric 3T MR Imaging in Prostate Cancer.

01-07-2016

Oncotarget

mTOR pathway activation is a favorable prognostic factor in human prostate adenocarcinoma.

31-05-2016

Genomics data

Androgen receptor DNA binding and chromatin accessibility profiling in prostate cancer.

01-03-2016

World journal of urology

Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin.

01-02-2016

The Prostate

Prognostic parameters for response to enzalutamide after docetaxel and abiraterone treatment in metastatic castration-resistant prostate cancer patients; a possible time relation.

01-01-2016

European journal of cancer (Oxford, England : 1990)

The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer.

01-11-2015

EMBO molecular medicine

Androgen receptor profiling predicts prostate cancer outcome.

01-11-2015

Clinical genitourinary cancer

Neoadjuvant taxane-based combination chemotherapy in patients with advanced penile cancer.

01-02-2015

BJU international

Occult lymph node metastases in patients with carcinoma invading bladder muscle: incidence after neoadjuvant chemotherapy and cystectomy vs after cystectomy alone.

01-07-2014

The Lancet. Oncology

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.

01-06-2014

Urology

Induction chemotherapy followed by surgery in node positive bladder cancer.

01-01-2014

The Journal of urology

FDG-positron emission tomography/computerized tomography for monitoring the response of pelvic lymph node metastasis to neoadjuvant chemotherapy for bladder cancer.

01-05-2013

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Response to induction chemotherapy and surgery in non-organ confined bladder cancer: a single institution experience.

01-04-2013

The Journal of urology

Carboplatin based induction chemotherapy for nonorgan confined bladder cancer--a reasonable alternative for cisplatin unfit patients?

01-10-2012

European journal of nuclear medicine and molecular imaging

18F-FDG PET/CT for monitoring induction chemotherapy in patients with primary inoperable penile carcinoma: first clinical results.

01-08-2010

Urologia internationalis

Pim1 regulates androgen-dependent survival signaling in prostate cancer cells.

11-03-2010

Androgen receptor moonlighting in the prostate cancer microenvironment.

Endogenous androgen receptor proteomic profiling reveals genomic subcomplex involved in prostate tumorigenesis.

Prognostic factors in men with metastatic castration-resistant prostate cancer treated with cabazitaxel.

The adaptive immune system promotes initiation of prostate carcinogenesis in a human c-Myc transgenic mouse model.

The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer.

Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial.

Effects of Budesonide on Cabazitaxel Pharmacokinetics and Cabazitaxel-Induced Diarrhea: A Randomized, Open-Label Multicenter Phase II Study.

Randomized Phase III Study to Assess Efficacy and Safety of Adjuvant CAPOX with or without Bevacizumab in Patients after Resection of Colorectal Liver Metastases: HEPATICA study.

Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.

Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer.

The Effects of Enzalutamide Monotherapy on Multiparametric 3T MR Imaging in Prostate Cancer.

mTOR pathway activation is a favorable prognostic factor in human prostate adenocarcinoma.

Androgen receptor DNA binding and chromatin accessibility profiling in prostate cancer.

Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin.

Prognostic parameters for response to enzalutamide after docetaxel and abiraterone treatment in metastatic castration-resistant prostate cancer patients; a possible time relation.

The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer.

Androgen receptor profiling predicts prostate cancer outcome.

Neoadjuvant taxane-based combination chemotherapy in patients with advanced penile cancer.

Occult lymph node metastases in patients with carcinoma invading bladder muscle: incidence after neoadjuvant chemotherapy and cystectomy vs after cystectomy alone.

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.

Induction chemotherapy followed by surgery in node positive bladder cancer.

FDG-positron emission tomography/computerized tomography for monitoring the response of pelvic lymph node metastasis to neoadjuvant chemotherapy for bladder cancer.

Response to induction chemotherapy and surgery in non-organ confined bladder cancer: a single institution experience.

Carboplatin based induction chemotherapy for nonorgan confined bladder cancer--a reasonable alternative for cisplatin unfit patients?

18F-FDG PET/CT for monitoring induction chemotherapy in patients with primary inoperable penile carcinoma: first clinical results.

Pim1 regulates androgen-dependent survival signaling in prostate cancer cells.

This site uses cookies